“Biotech & Life Science”
8:56 a.m. yesterday
Biogen, which has a major manufacturing facility in Durham, saw its stock spike sharply Thursday after an abstract on results from a Phase I Prime study on its Alzheimer's drug leaked.
5:33 a.m. Thursday
1:00 p.m. Wednesday
Reviewing SEC filings for November makes clear how busy the month was for North Carolina technology, life science and other emerging companies were in seeking to raise new capital. From A to Z, here's the list.
12:30 p.m. Wednesday
7:14 a.m. Wednesday
Securitization of supply chains, authentication of products, and preventing counterfeiting have challenged businesses for centuries. The problems continue to become more daunting as globalization and transfer of goods and products becomes more complex. The tools and techniques of Nanotechnology and Biotechnology are beginning to provide some answers to these challenges.
6:35 a.m. Wednesday
UVision, a young North Carolina biotechnology company, has filed to raise $2 million in equity, according to a filing with the Securities and Exchange Commission.
1:55 p.m. Tuesday
Locus Biosciences, a Raleigh-based company wants to raise $7 million in a private offering, according to a filing with the Securities and Exchange Commission.
Updated 1:50 p.m. Tuesday
G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, will team up with biotech pioneer Genentech on a cancer clinical trial in the new year.
9:35 a.m. Tuesday
Researchers from North Carolina State University have discovered a way to make pinpoint changes to an enzyme-driven "assembly line" that will enable scientists to improve or change the properties of existing antibiotics as well as create designer compounds.
Enzyme assembly line
8:24 a.m. Tuesday
Cempra says Toyama Chemical Co., a subsidiary of Fujifilm Holdings Corp., began Phase 3 clinical trials with its pneumonia-fighting drug in Japan, the world's second-largest antibiotic market.
Updated 2:35 p.m. Monday
Essex Woodlands, a $2.5 billion equity investment firm, is taking another $15 million stake in RTP-based Metabolon, which focuses on the growing field of metabolomics.
11:09 a.m. Monday
Dr. Dominique Limet is leaving after seven years as the CEO of GSK-owned ViiV Healthcare, which focuses on treatments for HIV. He will be replaced by GSK executive Deborah Waterhouse.
Updated 9:32 a.m. Monday
The year 2016 will draw to a busy close for Triangle tech firms with a host of events on the calendar. Here's the latest update plus a look at early 2017 and what groups meet where. and when.
Updated 6:32 a.m. Monday
5:25 a.m. Monday
Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part three.
5:20 a.m. Monday
Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part two.
5:15 a.m. Monday
Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part one.
5:10 a.m. Monday
WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.
Heat Biologics stock fell more than 50 percent in Thursday morning trading after the drug developer announced that its bladder cancer drug did not produce favorable results in a Phase 2 trial.